Number of eligible people: CDEC talked over the uncertainty in the volume of clients with moderately severe to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some people who will be categorized as possessing delicate or moderate illness may have a intense https://hemgenix38269.develop-blog.com/42995744/facts-about-hemgenix-revealed